BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Northwest Biotherapeutics Inc. NWBO
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.4M
▼ 0.3% vs FY2024
EPS · FY25
$-0.04
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-4365.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.4M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 4366 cents on every revenue dollar this year.
Per share
USD -0.04
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-4347.9%
Net margin-4365.9%
Return on assets-111.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+1.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−6.4%
+1.3%
−2.3%
+38.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
1.56B
Shares outstanding, FY2025
Change, 5 years+87.5%
Change, 10 years—
The share count grew 87% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 81.3M
total assets, end of FY2025
Total assetsUSD 81.3M
EquityUSD -60.3M
CashUSD 3.0M
Gross debtUSD 60.0M
Net debtUSD 57.0M
Current ratio0.06×
Net debt stands at -95% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
·
·
·
·
·
·
·
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.1
−0.1
0.2
−0.5
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.04
−0.07
−0.06
−0.10
−0.06
−0.73
−0.04
−0.12
−0.31
−0.77
−1.48
−2.29
−2.00
−5.72
−5.58
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
−365.9
Shares out B
1.56
1.33
1.18
1.07
0.95
0.83
0.61
0.52
0.33
0.16
0.10
0.07
0.05
0.02
0.01
0.07
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed